Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and admin

Change in fair value of acquisition consideration

Restructuring costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Twist Bioscience Corp

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. Its products include genes, oligo pools, Next Generation Sequencing (NGS), variant libraries, synthetic controls, antibody discovery, and SARS-CoV-2 Tools. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment consists of Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck on February 4, 2013 and is headquartered in San Francisco, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Twist Bioscience Corp meets Q1 expectations, eyes growth opportunities

Twist Bioscience Corp's Q1 performance met or exceeded expectations across key revenue segments, with a focus on expanding customer base and improving turnaround times.
While facing challenges such as COVID impact on China sales and margin dips due to fixed costs, the company aims for revenue growth and improved margins through strategic execution.
The company's strengths lie in strong gross margins, record bookings in NGS, and efforts towards DNA data storage alliances, positioning for future growth and innovation.
Opportunities include continued customer expansion, Fast Gene market development, and revenue growth driven by NGS and SynBio performance, amidst a value-based pricing strategy.

Twist Bioscience Corp achieves $60.2M revenue in Q2 2023

Twist Bioscience Corp's Q2 2023 earnings call highlighted strong revenue growth, cost reduction efforts, and a focus on achieving profitability. The company is navigating challenges in the biopharma sector while leveraging strengths in technology and sales execution for future growth.

Twist Bioscience Corp reports record Q3 revenue, focuses on growth

Twist Bioscience Corp delivered a strong performance in Q3, with record revenue and strategic product launches driving growth across key segments.
While facing challenges in biopharma revenue and commercial execution, the company is focused on expansion, talent acquisition, and cost management to drive future growth.
With a clear focus on innovation, market expansion, and achieving profitability milestones, Twist Bioscience Corp is well-positioned for future success and market leadership.
The company's strengths in SynBio products, strategic market positioning, and stable funding outlook underscore its potential for sustained growth and value creation.

Twist Bioscience Corp reports robust revenue growth and eyes profitability

Twist Bioscience Corp's Q4 2023 earnings call highlighted strong revenue growth, operational efficiency, and a solid financial position.
The company faces challenges in managing expenses and achieving profitability but sees opportunities in revenue growth and market expansion.
By leveraging strengths in product launches, customer relationships, and revenue growth, Twist Bioscience aims for continued success and margin expansion in fiscal 2024.

Twist Bioscience Corp excels in Q1 2024, focuses on growth

Twist Bioscience Corp's Q1 2024 earnings call highlighted robust revenue growth, margin expansion, and strategic focus on operational efficiency. The company's emphasis on customer needs, premium pricing, and cost efficiency positions it well for future growth and profitability.

Twist Bioscience reports robust Q2 revenue growth and margin targets

Twist Bioscience Corp delivered strong revenue growth and aims for margin improvement, driven by successful product lines and strategic initiatives.
While facing challenges in managing expenses and achieving profitability, the company is well-positioned to leverage market opportunities and regulatory advantages.
With a focus on innovation, market expansion, and margin growth, Twist is poised for continued success and competitive growth in the biopharma sector.
Navigating operational challenges and seizing growth opportunities will be crucial for Twist Bioscience to achieve its financial targets and sustain market leadership.

Twist Bioscience Corp reports robust Q3 revenue growth and profitability outlook

Twist Bioscience Corp delivered strong revenue growth and operational performance in Q3 2024, driven by robust NGS and biopharma revenue streams.
While facing challenges in achieving profitability targets, the company's focus on margin improvement and capacity expansion positions it for future growth.
Guidance for fiscal 2024 indicates promising revenue growth, highlighting opportunities for sustained expansion and enhanced financial performance.

Twist Bioscience Corp reports record revenue and aims for profitability

Twist Bioscience Corp delivered strong financial performance, with record revenue and margin growth driven by key product segments and operational efficiencies.
The company's focus on achieving adjusted EBITDA profitability and cash flow positivity, along with robust fiscal 2025 guidance, signals a path towards sustainable growth.
While challenges like cost management and market competition persist, opportunities in market traction, revenue diversification, and innovation position the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck in 2013 and is headquartered in San Francisco, CA.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that its Twist Biopharma division has signed two licensing agreements with Serotiny and Applied StemCell. In collaboration with Serotiny, Twist Biopharma aims to discover novel Chimeric Antigen Receptors (CAR) for CAR T-Cell therapies. The agreement with Applied StemCell,

Twist Bioscience Signs Two Biopharma Technology Agreements to Enable Novel Therapeutics Discovery

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has started shipping its new synthetic RNA reference controls, which includes the new variant strain of SARS-CoV-2 identified in the United Kingdom. With this new strain (B1.1.7 lineage, variant under investigation VUI-202012/01), which contains multiple mutations

Twist Bioscience Begins Shipping of Synthetic RNA Controls for UK Variant Strain of SARS-CoV-2

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #COVID19--Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it will supply the U.S. Centers for Disease Control and Prevention (CDC) with a customized version of Twist SARS-CoV-2 Synthetic RNA Controls for use in the CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay. The CDC SARS-CoV-2 (Flu SC2) Multiplex Assay tests for influenza

Twist Bioscience Supplies Centers for Disease Control and Prevention with Custom SARS-CoV-2 Synthetic RNA Controls

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11th at 5:20 p.m. Eastern Time. The presentation will be webcast live and can be accessed by visiting the “Investor Cale

Twist Bioscience to Present at the 39th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #COVID19--Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced plans to offer a new synthetic RNA control that includes the new variant of SARS-CoV-2 circulating in the United Kingdom and South Africa. This new variant strain of SARS-CoV-2 contains multiple spike protein mutations as well as mutations in other areas of the viral genom

Twist Bioscience to Offer Synthetic RNA Control for UK Variant Strain of SARS-CoV-2

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNADataStorage--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced plans to expand its manufacturing and commercial capabilities with the addition of the “Factory of the Future” just outside of Portland, Oregon in Wilsonville. The 110,000-square-foot facility is expected to become operational in 2022 and potentially bring up to 400 jobs t

Twist Bioscience to Expand Commercial Capabilities with Factory of the Future

Inovio Pharmaceuticals

Seres Therapeutics

Novavax

Pfizer

Investors favored coronavirus vaccine work, late-stage trial victories, and genetic sequencing.

These 5 Mid-Cap Healthcare Stocks Had the Best Gains in 2020

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of Clonal-Ready Gene Fragments, providing customers with a complete offering for genes. Twist's best-in-class Gene Fragments, with and without adapters, can be used to build constructs and minimize the time and cost of screening for perfect clones. “Our industry

Twist Bioscience Expands Gene Product Line with Launch of Clonal-Ready Gene Fragments

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the closing of its underwritten public offering of 3,211,362 shares of its common stock at a public offering price of $110.00 per share, which consists of 3,136,362 shares sold by Twist, including the exercise in full by the underwriters of their option to purchase up to a

Twist Bioscience Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the pricing of an underwritten public offering of 2,802,272 shares of its common stock at a price to the public of $110.00 per share, which consists of 2,727,272 shares to be sold by Twist and 75,000 shares to be sold by certain selling stockholders. The gross proceeds of

Twist Bioscience Announces Pricing of a $300 Million Upsized Public Offering of Common Stock

Celsius Holdings

Green Brick Partners

Taiwan Semiconductor Manufacturing

These stocks look ripe for a 2021 breakout. Seeking Alpha Top Stocks makes it easy to find the strongest stocks in the market.

These Stocks Are Ready For Their 2021 Breakout (Video)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will present at the following upcoming virtual investor conferences: Piper Sandler 32nd Annual Virtual Healthcare Conference, recorded fireside chat available at

Twist Bioscience to Present at Upcoming Virtual Investor Conferences

Twist Bioscience Corporation (TWST) CEO Emily Leprouston Q4 2020 Results - Earnings Call Transcript

Shares of Twist Bioscience (NASDAQ:TWST) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share increased 43.75% year over year to ($0.54), which beat the estimate of ($0.70).

Twist Bioscience: Q4 Earnings Insights

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the fourth quarter and full year fiscal 2020 ended September 30, 2020. “We ended our fiscal year with record revenue and orders against the backdrop of a global pandemic and significant uncertainty,” said Emily M. Leproust, Ph.D

Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2020 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (Nasdaq: TWST) today announced preclinical data for three of its proprietary antibodies against the S1 protein in SARS-CoV-2, the virus that causes COVID-19. The data show that TB202-3 and TB202-63, both single domain VHH “nanobodies,” protect against weight loss, a key indicator of disease severity, at the lowest dose of 1 mg/kg in a preclinical hamster challenge model. In addition, TB181-36, an IgG antibody discovered

Twist Bioscience Announces Positive Preclinical Data for SARS-CoV-2 Antibodies

On Monday, November 23, Twist Bioscience (NASDAQ: TWST) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.

Earnings Preview for Twist Bioscience

SOUTH SAN FRANCISCO, Calif. & NEW YORK--(BUSINESS WIRE)-- #COVID19--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Biotia, Inc., a company that uses proprietary analytical software for infectious disease diagnostics, today announced the availability of an important new research tool for the sequencing and surveillance of COVID-19. The companies have developed the SARS-CoV-2 Next-Generat

Twist Bioscience and Biotia Announce Research Use Only Availability of First Hybridization Capture-Based Next-Generation Sequencing SARS-CoV-2 Assay for Characterization and Surveillance of the Virus

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), today announced that it ranked 60th on Deloitte's Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies in North America now in its 26th year. “The entire team at Twist has been working very hard to innovate and execute, offering synthetic DNA and DNA products to enable our customers to improve health and sustainability,”

Twist Bioscience Ranked 60th Fastest Growing Company in North America on Deloitte's 2020 Fast 500™

Twist Bioscience (TWST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Twist Bioscience (TWST) Report Negative Earnings Next Week? What You Should Know

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the availability of the Twist Comprehensive Viral Research Panel, a next-generation sequencing (NGS) panel that includes more than 3,000 viral genomes to enable identification of new and divergent viral species in a single sample. The panel will be bundled with an analysis

Twist Bioscience Expands Infectious Disease Product Line Adding Comprehensive Viral Panel

SAN FRANCISCO & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced its continued partnership with the International Genetically Engineered Machine (iGEM) Foundation. As a long-time supporter of iGEM, in 2019 Twist provided a streamlined approach to change the way iGEM Competition teams contribute to the Registry of Standard Biologica

Twist Bioscience Continues Support for Next Generation of Synthetic Biologists Through Work with iGEM Competition

Illumina

Western Digital

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), Illumina, Inc. (NASDAQ: ILMN) and Western Digital (NASDAQ: WDC) today announced the formation of an alliance with Microsoft to advance the field of DNA data storage. These founding companies, alongside member organizations, will work together to create a comprehensive industry roadmap that will help the industry achieve interoperability between solutions and help establish the foundations for a cost-effec

Twist Bioscience, Illumina and Western Digital Form Alliance with Microsoft to Advance Data Storage in DNA

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16 at 4:40 p.m. Eastern Time. The presentation will be webcast live and can be accessed by visiting the “Presentations” pag

Twist Bioscience to Present at the Stifel 2020 Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2020 fourth quarter and full year ended September 30, 2020, before the opening of the market on Monday, November 23, 2020. The company plans to hold a conference call and live audio webcast for analysts and investors

News for Twist Bioscience Corp Stock (TWST)